Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Income towards Parent Company (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Income towards Parent Company readings, the most recent being $1.7 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 88.53% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$27.1 million, a 51.68% increase, with the full-year FY2025 number at -$27.1 million, up 51.68% from a year prior.
  • Income towards Parent Company hit $1.7 million in Q4 2025 for Amicus Therapeutics, down from $17.3 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $17.3 million in Q3 2025 to a low of -$85.3 million in Q1 2022.
  • Median Income towards Parent Company over the past 5 years was -$38.5 million (2023), compared with a mean of -$36.1 million.
  • The widest YoY moves for Income towards Parent Company: up 357.19% in 2025, down 88.53% in 2025.
  • Amicus Therapeutics' Income towards Parent Company stood at -$83.3 million in 2021, then skyrocketed by 32.92% to -$55.9 million in 2022, then soared by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then crashed by 88.53% to $1.7 million in 2025.
  • The last three reported values for Income towards Parent Company were $1.7 million (Q4 2025), $17.3 million (Q3 2025), and -$24.4 million (Q2 2025) per Business Quant data.